Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022.
Net income was $69.4 million, or $1.04 per diluted share, compared to $1.6 million, or $0.03 per diluted share, for Q1 2022.
As of March 31, 2023, cash and cash equivalents were $1.2 billion, and the outstanding principal balance of the company's long-term debt was $5.8 billion. In addition, the company had undrawn borrowing capacity under a revolving credit facility of $500 …